Active Biotech in Brief

Active Biotech develops pharmaceutical products within medical areas where the immune system is of significant importance, including cancer and inflammatory eye diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.

Active Biotech has its base in Lund, Sweden and was formed in 1998 as a spin-off from Pharmacia & Upjohn. The share is listed and traded on Nasdaq Stockholm (Small Cap). The Company has core competence in cancer and inflammatory diseases and a competent team with extensive experience in drug development from early to late stage clinical development.

The project portfolio is composed of:

• Tasquinimod, targeted towards hematological malignancies is in clinical phase Ib/IIa for the treatment of myelofibrosis and multiple myeloma
• Laquinimod, targeted towards inflammatory eye disorders, has been subject to a clinical phase I trial with an eye drop formulation. A clinical biodistribution study after administration of the eye drop formula for patients is ongoing
• Naptumomab estafenatox (Naptumomab), licensed to NeoTX Therapeutics Ltd., is in clinical development for treatment of solid tumors. A phase Ib/II study in selected solid tumors are ongoing